Longevity Lab Report

Explainer

What Does the Evidence Say About Omega-3 for Longevity?

The split among three large trials, the capsule arithmetic that decides whether a bottle matches a trial, the expert index target, and our B grade.

Saved articles

Ask ChatGPT about this article ↗

Copy the prompt, then paste it into ChatGPT to explore the findings and sources.

Open ChatGPT ↗

The findings

Omega-3 lowers triglycerides reliably at high doses. For living longer the large trials split: REDUCE-IT, a prescription EPA product at 4 grams a day in high-risk patients, cut events by about 25 percent, while VITAL and STRENGTH found no significant benefit. No trial shows omega-3 extending lifespan.

Explore the study: What did VITAL find about fish oil and heart events?

Omega-3 lowers triglycerides reliably at high doses, and that is its strongest claim. For living longer, the evidence is mixed: one large prescription EPA trial cut cardiovascular events, two large general population trials did not. No trial shows omega-3 extending lifespan. Food and dose explain most of the split.

What the trials show

Start with the claim nobody contests. High dose EPA and DHA reliably lower triglycerides in trials. Our record grades that claim strong. If triglycerides are the goal, the tested range is the top of the record's range, 1 to 4 grams of combined EPA and DHA per day, with the higher end used under a doctor's care, and the fair test is a blood panel after 8 to 12 weeks [1].

The cardiovascular record splits by trial, dose, and population. REDUCE-IT randomized 8,179 patients with high triglycerides on statins to icosapent ethyl, a prescription EPA product, at 4 grams per day or placebo, and found about a 25 percent lower risk of the primary event composite. That is the strongest positive result in the modern record, and it belongs to a prescription drug, at a treatment dose, in a high risk population [2].

The two large tests closest to the general buyer point the other way. VITAL randomized 25,871 adults to about 1 gram per day of EPA plus DHA or placebo and found no significant reduction in its primary cardiovascular or cancer endpoints. STRENGTH randomized 13,078 high risk patients to 4 grams per day of a combined EPA and DHA product or corn oil, and was stopped early for futility, with more atrial fibrillation in the omega-3 group. Three large trials, one positive and two null. Dose alone does not explain the split, since STRENGTH matched REDUCE-IT on grams and differed on form and comparator [3][4].

For longevity itself, there is no direct trial result to cite. No randomized trial shows omega-3 extending lifespan. The marker studies behind the aging headlines point in different directions: the VITAL telomere substudy found no effect on telomere shortening, while a DO-HEALTH substudy reported omega-3 slowing three of four epigenetic aging clocks by roughly three months over three years. Clocks and telomeres are markers, not aging outcomes. Our record claims no aging benefit [5].

Mood is the remaining common claim. Some meta-analyses suggest a benefit in depression, mainly for EPA dominant formulas. Our record grades it emerging, not settled.

The capsule problem

Most omega-3 confusion is arithmetic, not biology. A standard 1,000 mg fish oil capsule holds only about 300 mg of EPA plus DHA. The dose that matters is the second number: the EPA and DHA lines on the Supplement Facts panel added together. Reaching 1 gram per day takes three or more standard capsules, and the 2 to 3 gram range some experts target takes seven to ten. A reader who takes one standard capsule a day has tested about 300 mg, below every range in this article.

What the experts say

Every quote below comes from our expert database, copied word for word, with its source linked. Positions without a verified quote are labeled as positions, not quotes.

Peter Attia targets a blood measure rather than a capsule count: "The optimal omega-3 index (the amount of EPA plus DHA in red blood cell membranes) is 8-12%". His own intake, per our record, is roughly 2 grams of EPA plus 1.5 grams of DHA daily, well above what one or two standard capsules deliver. https://podcastnotes.org/the-drive-with-dr-peter-attia/omega-3-omega-6-epa-dha-fish-oil-peter-attia-bill-harris/

Rhonda Patrick lands in the same range from the index side: "you want to have at least, you know, 1.5 to 2 grams a day to get you to a high Omega-3 Index". https://www.foundmyfitness.com/episodes/rhonda-patrick-top-5-supplements

Andrew Huberman frames it as a food gap filler: "Supplementing with EPA & omega-3 if you don't consume enough fish (1.5-2g EPA) is a good idea". The condition matters: the recommendation is aimed at people who do not eat enough fish, not at everyone. https://podcastnotes.org/huberman-lab/episode-42-nutrients-for-brain-health-performance-huberman-lab/

Examine.com covers omega-3 with triglyceride lowering as the established use and the wider claims as unsettled, which matches our record.

The experts agree more than the trials do. All three target roughly 1.5 to 3.5 grams a day, or the blood index that range produces, and treat fatty fish intake as the variable that decides whether a supplement is needed. None claims a lifespan result, because no trial gives them one.

Our grade and rationale

Longevity Lab Report grades omega-3 B on evidence and B on worth it, at $15 to $25 a month.

The B is built on the triglyceride claim, which is strong, held back by everything around it: a cardiovascular record that splits one positive against two null in the largest modern trials, an emerging mood claim, and no longevity outcome data at all. It is a good grade for a narrow, proven job. It would be a dishonest grade for the broad promise on most bottles.

The worth it B follows from broad applicability and a mid range cost at a real dose. The cost assumes a product that delivers the EPA and DHA on its label. Quality varies in this market, and rancidity is a real concern with cheap products. A bottle that delivers a third of the labeled dose is not the product this grade prices.

How we grade: https://longevitylabreport.com/methodology Full record: https://longevitylabreport.com/ingredients/omega-3

Safety

Omega-3 is generally safe at typical doses. High doses can thin the blood slightly, which matters before surgery or with anticoagulants, and the STRENGTH trial adds a second high dose caution: more atrial fibrillation in the omega-3 group. Quality varies, and rancidity is a real concern with cheap products. Talk to your doctor if you take blood thinners. This page is information, not medical advice.

Frequently asked questions

How much fish oil should I take per day? Count EPA plus DHA, not fish oil. Our record's range across trials is 1 to 4 grams of combined EPA and DHA per day, with the higher end for triglycerides under a doctor's care. A standard capsule holds about 300 mg of EPA plus DHA.

What should my omega-3 index be? The target in our expert record, from Peter Attia, is 8 to 12 percent. Whether the index itself causes better outcomes or only marks the diet that produces them is unproven, which the limitations section below states in full. The index reflects intake over preceding weeks, so give any change 8 to 12 weeks before retesting.

Can I get enough omega-3 from food alone? That is the Huberman framing: supplementation is the fix for not eating enough fatty fish. Two servings a week puts most people near the low end of the expert range.

Does omega-3 slow aging? Not proven. The two marker studies point in different directions, no trial shows an effect on lifespan, health, or function, and our record claims no aging benefit.

Limitations: what we do not know

We do not know why REDUCE-IT succeeded where STRENGTH failed at the same gram dose: form, comparator oil, and population all differ, and no head to head trial separates them. We do not know whether the omega-3 index is a cause of better outcomes or a marker of the diet and health that produce them. We do not know whether the atrial fibrillation signal at high doses outweighs the triglyceride benefit for any given patient; that is a clinician's call. What would change the grade: a large outcomes trial of a standard EPA plus DHA product, at a stated dose, in a general population.

Sources

  1. Longevity Lab Report omega-3 record (last updated 2026-10-17): triglyceride claim graded strong; dosage 1 to 4 g combined EPA/DHA per day; timing per verified question blocks, 2026-10-27.
  2. Bhatt et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med, 2019. n = 8,179.
  3. Manson et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med, 2019. n = 25,871.
  4. Nicholls et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA, 2020. n = 13,078.
  5. VITAL telomere substudy and DO-HEALTH epigenetic clock substudy, as logged in the Longevity Lab Report question bank verification, 2026-10-25.

Changelog

  • 2026-11-04: Draft created for Bill review. Not published. Grades and quotes from the omega-3 record (updated 2026-10-17). Panel review and Humanizer gate still to run. Editor note: Research to confirm REDUCE-IT and STRENGTH figures before any publish recommendation.
  • 2026-11-11: Panel PASS (research/article-panel-review-2026-11-11.md); Humanizer 92 (research/article-humanizer-2026-11-11.md), with one fix applied at that gate on the panel's note: the omega-3 index FAQ now carries the record's own caution that the index's causal status is unproven, so the FAQ does not read stronger than the body at snippet distance. Bill's review step removed by his daily-cadence order the same day; publication slot Nov 12, pending the Research confirmation above and the ship-time cold read.

Changelog

  • 2026-11-12: Published. Panel review passed 2026-11-11 (research/article-panel-review-2026-11-11.md); Humanizer 92 the same day (research/article-humanizer-2026-11-11.md), including the index FAQ caution added at that gate; REDUCE-IT and STRENGTH figures confirmed against the primary papers by Research 2026-11-11 (research/article-confirmations-2026-11-11.md); ship cold read passed 2026-11-11 (research/ship-files/2026-11-12-omega-3-article-cold-read.md), with lastReviewed carrying the publication date per the suite's date rule.

Supplements mentioned

Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.

Keep exploring

View all

The weekly newsletter

Keep up with what’s changing.

New research, useful tools, and the people shaping health and longevity. Selected and explained in one email.

See what you’ll receive ↗

Free. Confirm your email to subscribe. Unsubscribe anytime.